

MCRALE & SLAVIN, P.A.
ATTORNEYS AT LAW

PALM BEACH
FIRST UNION CENTER
SUITE 402, 4440 PGA BOULEVARD
PALM BEACH GARDENS, FLORIDA 33410
e-mail: palmbeach@mspatents.com
TELEPHONE (561) 625-6575
FACSIMILE (561) 625-6672

U.S. & INTERNATIONAL
PATENTS, TRADEMARKS, COPYRIGHTS,
RELATED LICENSING & LITIGATION

MIAMI
e-mail: miami@mspatents.com
TELEPHONE (305) 374-3311
FACSIMILE (305) 374-5232

CHICAGO
e-mail: chicago@mspatents.com
TELEPHONE (312) 939-2815

February 13, 2003

FAX RECEIVED
FEB 13 2003
GROUP 1600

TELECOPIER COVER SHEET

TO: Examiner Cheyne Ly
U.S. Patent and Trademark Office

TELECOPIER NO.: (703) 308-4242

FROM: Susan Hess
Legal Assistant to Ferris Lander

PAGES INCLUDED: 7 (including cover sheet)

TELECOPIER NO.: (561) 625-6572

REGARDING: U.S. Patent Applu Serial No. 09/845,715
Our Ref: 2132.030

OFFICIAL

SPECIAL INSTRUCTIONS:

Attached please find a Transmittal Letter and Rcsponse to Examiner's Office Action for the above-identified application.

Please contact me if you have any questions regarding this matter. Thank you for your assistance.

PRIVACY AND CONFIDENTIALITY NOTICE

The information contained in the facsimile transmission is confidential and private; it is intended to be disclosed only to the individual(s) to whom it is addressed. Any other person who reads, uses and/or discloses the information it contains may be violating Federal and/or State rights of the sender and the intended recipient(s). If this fax has been transmitted to the wrong number, please immediately destroy it and notify the sender of the mistaken transmission by fax or telephone.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below to Examiner Cheyne Ly at (703) 308-4242.

Date: 2-13-03

Susan Hess
Susan Hess

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.
INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE
STATE HAVING A MOLECULAR WEIGHT OF
1348 DALTONS
SERIAL NUMBER : 09/845,715
FILING DATE : April 30, 2001
EXAMINER: : Ly, Cheyne
GROUP ART UNIT : 1631
ATTORNEY DOCKET NO. : 2132.030

TRANSMITTAL LETTER

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

Sir:

Please find enclosed for filing:

X Response to Office Action of January 13, 2003
X Please charge any deficiencies or credit any overpayment to Deposit Account No. 50-1803.

Respectfully submitted,


34,016
Dennis H. Lander
Registration No. 43,377
McHale & Slavin, P.A.
4440 PGA Boulevard, Suite 440
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575

Date: 2/13/03

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below to Examiner Cheyne Ly at (703) 308-4242.

Date: 2-13-03Susan Hess

Susan Hess

#17
Plunkett
2/23/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : JACKOWSKI et al.

INVENTION: : BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 1348 DALTONS

SERIAL NUMBER : 09/845,715

FILING DATE : April 30, 2001

EXAMINER: : Ly, Cheyne

GROUP ART UNIT : 1631

ATTORNEY DOCKET NO. : 2132.030

RESPONSE TO OFFICE ACTION OF JANUARY 13, 2003

Box Non-Fee Amendment
Commissioner for Patents
Washington, D.C.

Sir:

In response to the Requirement for Restriction dated January 13, 2003, having a shortened statutory period for response set to expire February 13, 2003, kindly enter the following response:

Restriction to one of the following inventions has been required under 35 USC 121:

- I. Claims 1-2, are drawn to a biopolymer marker having a sequence identified as SEQ ID NO: 1 useful in indicating at least one particular disease state, classified in class 530, subclass 300.
- II. Claims 3-9, drawn to a method for evidencing and categorizing at least one disease state, classified in class 702, subclass 19.
- III. Claims 10-28 and 33-34, drawn to a diagnostic assay kit and method for determining the presence of the biopolymer marker or analyte thereto and determining risk-assessment, and identifying therapeutic avenues related to a disease state, classified in classes 422 and 436, subclasses 61 and 63. If this Group is elected, then the below summarized species election is also required.
- IV. Claims 29-32, drawn to an antibody that specifically binds a biopolymer including the marker sequence identified as SEQ ID NO: 1 or at least one analyte thereof, classified in class 530, subclass 387.1.
- V. Claim 35, drawn to a process for regulating a disease state by controlling the presence or absence of a biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof, classified in class 514, subclass 2.

Applicants hereby elect, with traverse, the Group I invention, for further prosecution on the merits.

It is understood that claims 3-35, drawn to the non-elected invention, will remain pending, albeit withdrawn from further consideration in this application.

SUMMARY

This case is related, in claim format to several pending applications of which S.N.